ArticleDiabetes, obesity & metabolism2026
Trends in Prevalence of Diabetes, Pre-Diabetes, and Cardiometabolic Risk Factor Control Among U.S. Adults, 2013-2023.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trends in Prevalence of Diabetes, Pre-Diabetes, and Cardiometabolic Risk Factor Control Among U.S. Adults, 2013-2023.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
aimsThe objective of this study was to estimate the prevalence and trends in prevalence of dysglycemia in the United States (U.S.).
methodsThis is a repeat cross-sectional analysis of adults age ≥ 20 years who participated in the National Health and Nutrition Examination Survey (NHANES) between 2013-2023. Age-standardized pre-diabetes, undiagnosed diabetes, diagnosed diabetes, and total diabetes prevalence were estimated for each of the 4 survey cycles, then stratified by sociodemographic and clinical characteristics. Linear trends were estimated using logistic regression. Prevalence calculations and trend analyses were repeated to assess the proportion of participants meeting glycemic, blood pressure, and lipid control targets.
resultsAmong 24 230 participants across all survey years, 6773 had pre-diabetes, and 4784 had diabetes (3826 diagnosed/958 undiagnosed). The age-adjusted prevalence of total diabetes was stable across the study period: 14.6% (95% CI 13.0%-16.2%) in 2013-2014 and 16.3% (14.6%-18.0%) in 2021-2023 (prevalence ratio (PR) 1.07 [95% CI 0.90-1.26], p-trend = 0.47). The age-adjusted prevalence of pre-diabetes increased significantly during the study period from 26.4% (23.7%-29.1%) in 2013-2014 to 30.7% (28.4%-33.0%) in 2021-2023 (p-trend = 0.04, PR 1.12 [1.02-1.23]).
conclusionWhile the prevalence of diabetes has stabilized over the last decade, the rise in pre-diabetes signals a growing population at risk for future cardiometabolic and kidney disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.